$TRAX

$43.48 -$0.57 (1.29%) Close

$TRAX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 35.7M shares outstanding

Who owns TRAX?

By type of holder

Institutions 95.4% Insiders 4.7% Everyone else 0.0%

Concentration Top 10 holders own 52.3%

EcoR1 Capital, LLC 8.9% · TCG Crossover Management, LLC 8.1%

Institutional ownership

95.4%

+95.4 pts vs last qtr

Institutional holders

149

+149 vs last qtr

Net shares bought

+34.1M

by institutions in Q2 2026

New / sold out

149 / 0

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

EcoR1 Capital, LLC NEW +3.2M
TCG Crossover Management, LLC NEW +2.9M

Biggest sellers in Q2 2026

None.

Who is planning to sell?

Notices of proposed sale, last 12 months

$1.76M

1 notice from 1 person

Shares covered

39.3K

0.11% of the company

Arranged in advance

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

Joe Anthony Ware Director $1.76M

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

There are not yet two fiscal years of reported share counts for First Tracks Biotherapeutics Inc.

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years0% Under 1 year100%

Quarterly turnover

—

of institutional shares changed hands

Top 10 managers, median time held

0 quarters

Super Investors

Investment managers reporting TRAX on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
EC EcoR1 Capital, LLC	3.2M	8.88%	NEW	Q2 '26	3.1%
Shares held by quarter Peak holding3.2M (Q2'26) Change over 8 quarters+3.2M Share of the company8.880% EcoR1 Capital, LLC's full portfolio →
TC TCG Crossover Management, LLC	2.9M	8.10%	NEW	Q2 '26	1.4%
Shares held by quarter Peak holding2.9M (Q2'26) Change over 8 quarters+2.9M Share of the company8.100% TCG Crossover Management, LLC's full portfolio →

EcoR1 Capital, LLC

3.2M

% of company

8.88%

Change vs last qtr

NEW

Held since

Q2 '26

TCG Crossover Management, LLC

2.9M

% of company

8.10%

Change vs last qtr

NEW

Held since

Q2 '26

23 more super investors behind a free account

See every manager holding First Tracks Biotherapeutics Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting TRAX on Form N-PORT; together they hold 21.3% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$22.4M	1.1M	3.11%	0.00%	June 30, 2026
SS State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR Series Trust	$18.7M	930.4K	2.60%	0.17%	June 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$22.4M

% of company

3.11%

% of the fund

0.00%

As of

June 30, 2026

State Street(R) SPDR(R) S&P(R) Biotech ETF

SPDR Series Trust

Position value

$18.7M

% of company

2.60%

% of the fund

0.17%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding First Tracks Biotherapeutics Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
FD Faga Daniel Insider	496.7K	1.39%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company1.390% Faga Daniel's insider activity →
LP Lizzul Paul F. Insider	42.7K	0.12%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company0.120% Lizzul Paul F.'s insider activity →

Faga Daniel

Insider

496.7K

% of company

1.39%

Change vs last qtr

—

Held since

—

Lizzul Paul F.

Insider

42.7K

% of company

0.12%

Change vs last qtr

—

Held since

—

8 more holders behind a free account

See every insider and 5%+ holder of First Tracks Biotherapeutics Inc.

Comments